The biomolecule corona mediates pulmonary delivery of nanomedicine
-
Published:2024-09
Issue:
Volume:202
Page:114420
-
ISSN:0939-6411
-
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
-
language:en
-
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics
Author:
Subramaniam Santhni,
Joyce Paul,
Prestidge Clive A.ORCID
Reference38 articles.
1. Pulmonary delivery of therapeutic siRNA;Lam;Adv. Drug Deliv. Rev.,2012
2. K. Dua, R. Wadhwa, G. Singhvi, V. Rapalli, S.D. Shukla, M.D. Shastri, G. Gupta, S. Satija, M. Mehta, N. Khurana, R. Awasthi, P.K. Maurya, L. Thangavelu, R. S, M.M. Tambuwala, T. Collet, P.M. Hansbro, D.K. Chellappan, The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress, Drug Devel. Res., 80 (2019) 714-730.
3. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy;Jin;Adv. Drug Deliv. Rev.,2023
4. Proteomics of bronchoalveolar lavage fluid;Wattiez;J. Chromatogr. B,2005
5. What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?;Kumar;Nanomedicine,2015